Marrone Bio Innovations (NASDAQ:MBII) has been assigned a $4.00 price target by equities research analysts at HC Wainwright in a note issued to investors on Thursday. The firm presently has a “buy” rating on the basic materials company’s stock. HC Wainwright’s price target points to a potential upside of 280.95% from the company’s previous close.

Separately, ValuEngine lowered shares of Marrone Bio Innovations from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $2.50.

Marrone Bio Innovations (MBII) traded down $0.03 during mid-day trading on Thursday, hitting $1.05. 64,600 shares of the company were exchanged, compared to its average volume of 95,731. Marrone Bio Innovations has a 1 year low of $0.85 and a 1 year high of $2.45. The company has a quick ratio of 0.36, a current ratio of 0.69 and a debt-to-equity ratio of -1.14.

An institutional investor recently raised its position in Marrone Bio Innovations stock. Ardsley Advisory Partners increased its stake in Marrone Bio Innovations Inc (NASDAQ:MBII) by 375.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,681,580 shares of the basic materials company’s stock after buying an additional 2,907,142 shares during the quarter. Ardsley Advisory Partners owned about 11.74% of Marrone Bio Innovations worth $4,528,000 as of its most recent SEC filing. 37.59% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Marrone Bio Innovations (MBII) Given a $4.00 Price Target by HC Wainwright Analysts” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/12/21/marrone-bio-innovations-mbii-given-a-4-00-price-target-by-hc-wainwright-analysts.html.

Marrone Bio Innovations Company Profile

Marrone Bio Innovations, Inc offers bio-based pest management and plant health products. The Company’s bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate and Majestene.

Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with MarketBeat.com's FREE daily email newsletter.